Get the Stockscreener App
280.68
1.95%
5.36
Penumbra Inc stock is traded at $280.68, with a volume of 711.18K.
It is up +1.95% in the last 24 hours and up +1.04% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$275.32
Open:
$276.41
24h Volume:
711.18K
Relative Volume:
1.35
Market Cap:
$10.87B
Revenue:
$1.24B
Net Income/Loss:
$42.23M
P/E Ratio:
264.79
EPS:
1.06
Net Cash Flow:
$150.33M
1W Performance:
-5.60%
1M Performance:
+1.04%
6M Performance:
+18.01%
1Y Performance:
+39.27%
1-Day Range:
$272.99
$281.63
1-Week Range:
$265.00
$302.49
52-Week Range:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
280.68 | 11.51B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Insider Sell Alert: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Here's Why Penumbra (PEN) is a Strong Momentum Stock - Yahoo Finance
Penumbra EVP Johanna Roberts sells $268,697 in stock - Investing.com
Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance
Stroke Awareness Month: Quick Action Can Save Lives - ABC Action News
Transcript : Penumbra, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
PEN Q1 Earnings Call: U.S. Thrombectomy Drives Outperformance as International Headwinds Persist - Yahoo Finance
PEN INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Continues Penumbra (PEN) Fraud Investigation In Light Of Company’s Admissions, Encourages Investors to Contact its Attorneys Now - ACCESS Newswire
Penumbra stock surges on approval hopes By Investing.com - Investing.com Canada
Should You Consider Adding Penumbra (PEN) To Your Portfolio? - Insider Monkey
Penumbra CFO Maggie Yuen sells $598,020 in common stock - Investing.com
3 Mid-Cap Medical Stocks Outperforming the Market - The Globe and Mail
Penumbra’s SWOT analysis: stock poised for growth amid innovation and challenges - Investing.com Australia
LAWSUIT FILED: Penumbra, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP - ACCESS Newswire
SHAREHOLDER ALERT: Penumbra, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm - ACCESS Newswire
Penumbra Inc.: Can Its Innovation & Product Pipeline Foster Long-Term Growth & Competitiveness? - Smartkarma
Penumbra, Inc. Reports First Quarter 2025 Financial Results - Eastern Progress
We Think You Can Look Beyond Penumbra's (NYSE:PEN) Lackluster Earnings - simplywall.st
Penumbra, Inc. to Present at the BofA Securities 2025 Health Car - GuruFocus
Exclusive: Penumbra Management Team Set for Key Presentation at BofA Healthcare Conference - Stock Titan
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference - Longview News-Journal
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
3 Reasons Growth Investors Will Love Penumbra (PEN) - Yahoo Finance
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Ischemic Neurological Interventional Medical Devices Market - openPR.com
Penumbra projects 12%-14% revenue growth for 2025 amid strong thrombectomy performance - MSN
Penumbra, Inc. (NYSE:PEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings Beat: Penumbra, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Penumbra, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Penumbra EVP Roberts sells shares worth $180,006 By Investing.com - Investing.com Canada
Penumbra Inc. Earnings Call Highlights Strong U.S. Growth - TipRanks
Penumbra EVP Roberts sells shares worth $180,006 - Investing.com
Abstract 160: Utilization of Penumbra MIDWAY 43 Catheter in Complex Neurovascular Interventions: Case Study Analysis - American Heart Association Journals
Stifel raises Penumbra stock price target to $318 - Investing.com Australia
Penumbra Reaches Analyst Target Price - Nasdaq
Penumbra First Quarter 2025 Earnings: Beats Expectations - Yahoo
Gabriel Grego, Police Investigator Among Short Sellers [In-Depth Profile] - ValueWalk
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst - Benzinga
Penumbra Inc (PEN) Trading 6.02% Higher on Apr 24 - GuruFocus
UBS raises Penumbra stock price target to $330, maintains Buy rating - Investing.com
Stifel raises Penumbra stock price target to $318 By Investing.com - Investing.com South Africa
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand - Yahoo Finance
UBS Adjusts Price Target on Penumbra to $330 From $320, Maintains Buy Rating - marketscreener.com
Truist Boosts Penumbra (PEN) Price Target Following Strong Q1 Pe - GuruFocus
Truist Boosts Penumbra (PEN) Price Target Following Strong Q1 Performance | PEN Stock News - GuruFocus
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.85%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):